458
Participants
Start Date
September 28, 2020
Primary Completion Date
September 30, 2028
Study Completion Date
September 30, 2029
Lisaftoclax (APG-2575)
Lisaftoclax (APG-2575) orally once daily, every 28 days as a cycle.
Reduced-dose HHT
1mg IV QD on Days 1-14 (28-day cycle).
standard-dose HHT
2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
Azacitidine
75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
Lisaftoclax (APG-2575)
Lisaftoclax (APG-2575) orally once daily for 14 days, every 28 days as a cycle.
olverembatinib
orally, with meals, QOD, every 28 days as a cycle.
RECRUITING
Peking University People's Hospital, Beijing
RECRUITING
the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou
RECRUITING
Union Hospital medical college Huazhong University of Science and Technology, Wuhan
RECRUITING
Zhongnan Hospital of Hunan university, Wuhan
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
Chongqing University Cancer Hospital, Chongqing
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Henan Tumor Hospital, Zhengzhou
RECRUITING
Xiangya Hospital Central South University, Changsha
RECRUITING
The First affiliated hospital of Soochow University, Suzhou
NOT_YET_RECRUITING
Shanghai The Sixth People' s Hospital, Shanghai
Lead Sponsor
Suzhou Yasheng Pharmaceutical Co., Ltd.
INDUSTRY
Ascentage Pharma Group Inc.
INDUSTRY